Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.

MLA

Castagnetti, Fausto, et al. “Results of High-Dose Imatinib Mesylate in Intermediate Sokal Risk Chronic Myeloid Leukemia Patients in Early Chronic Phase: A Phase 2 Trial of the GIMEMA CML Working Party.” Blood, vol. 113, no. 15, Apr. 2009, pp. 3428–34. EBSCOhost, https://doi.org/10.1182/blood-2007-08-103499.

APA

Castagnetti, F., Palandri, F., Amabile, M., Testoni, N., Luatti, S., Soverini, S., Iacobucci, I., Breccia, M., Rege Cambrin, G., Stagno, F., Specchia, G., Galieni, P., Iuliano, F., Pane, F., Saglio, G., Alimena, G., Martinelli, G., Baccarani, M., & Rosti, G. (2009). Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood, 113(15), 3428–3434. https://doi.org/10.1182/blood-2007-08-103499

Chicago

Castagnetti, Fausto, Francesca Palandri, Marilina Amabile, Nicoletta Testoni, Simona Luatti, Simona Soverini, Ilaria Iacobucci, et al. 2009. “Results of High-Dose Imatinib Mesylate in Intermediate Sokal Risk Chronic Myeloid Leukemia Patients in Early Chronic Phase: A Phase 2 Trial of the GIMEMA CML Working Party.” Blood 113 (15): 3428–34. doi:10.1182/blood-2007-08-103499.